AbstractAimsA bone‐invasive pituitary adenoma exhibits aggressive behavior, leading to a worse prognosis. We have found that TNF‐α promotes bone invasion by facilitating the differentiation of osteoclasts, however, before bone‐invasive pituitary adenoma invades bone tissue, it needs to penetrate the dura mater, and this mechanism is not yet clear.MethodsWe performed transcriptome microarrays on specimens of bone‐invasive pituitary adenomas (BIPAs) and noninvasive pituitary adenomas (NIPAs) and conducted differential expressed gene analysis and enrichment analysis. We altered the expression of TNF‐α through plasmids, then validated the effects of TNF‐α on GH3 cells and verified the efficacy of the TNF‐α inhibitor SPD304. Finally, the effects of TNF‐α were validated in in vivo experiments.ResultsPathway act work showed that the MAPK pathway was significantly implicated in the pathway network. The expression of TNF‐α, MMP9, and p‐p38 is higher in BIPAs than in NIPAs. Overexpression of TNF‐α elevated the expression of MAPK pathway proteins and MMP9 in GH3 cells, as well as promoted proliferation, migration, and invasion of GH3 cells. Flow cytometry indicated that TNF‐α overexpression increased the G2 phase ratio in GH3 cells and inhibited apoptosis. The expression of MMP9 was reduced after blocking the P38 MAPK pathway; overexpression of MMP9 promoted invasion of GH3 cells. In vivo experiments confirm that the TNF‐α overexpression group has larger tumor volumes. SPD304 was able to suppress the effects caused by TNF‐α overexpression.ConclusionBone‐invasive pituitary adenoma secretes higher levels of TNF‐α, which then acts on itself in an autocrine manner, activating the MAPK pathway and promoting the expression of MMP9, thereby accelerating the membrane invasion process. SPD304 significantly inhibits the effect of TNF‐α and may be applied in the clinical treatment of bone‐invasive pituitary adenoma.

100 Deals associated with SPD-304

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Inflammation	Preclinical	FR	Peptinov SAS	15 Sep 2021
Rheumatoid Arthritis	Preclinical	US	Sunesis Pharmaceuticals, Inc.	11 Nov 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

SPD-304

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation